Bcl-2 protein level in blood of patients with acute myeloid leukaemia
Synthese(2016)
Abstract
We investigated the association between blood bcl-2 protein and the occurrence of acute myeloid leukaemia (AML), bcl-2 being an anti-apoptotic protein incriminated in cancer. Blood specimens were collected from 28 patients with AML, either de novo or following myelodysplastic syndrome, and from 25 healthy unrelated controls. In some specimens, the pro-apoptotic p53 protein and oligonucleosomes were also determined. In controls, bcl-2 was at 90.6 ± 27.8 U/ml, whereas p53 was detected in only 72 % of the specimens (0.15 ± 0.17 ng/ml); bcl-2 and p53 levels were inversely correlated. Oligonucleosomes were detected in all the controls but at low level and with no correlation to bcl-2 or p53. Bcl-2 level was higher in AML patients than in controls and some more increased in patients with de novo AML than in patients with secondary AML. In overall patients, bcl-2 correlated to lactico-dehydrogenase and to blood leukocytes, but weakly to blasts, and not to caryotype, cd-34 antigen and mdr-1 genotype. p53 was detected in only one patient with AML and oligonucleosomes were higher in patients than in controls. Studied on 12 patients without cytogenetic poor prognosis, bcl-2 level correlated to bad outcome. These data suggest that blasts that over express bcl-2 are resistant to apoptosis, defining this protein as a factor of bad prognosis in AML. Moreover, the determination of normal ranges for bcl-2 protein may be instrumental in the study of various diseases where apoptosis is enhanced, disrupted or delayed. Keywords: bcl-2; acute myeloid leukaemia; apoptosis; myelodysplastic syndrome; p53. Nous avons recherche la relation entre la proteine bcl-2 dans le sang et l’existence d’une leucemie myeloide aigue (LMA), bcl-2 etant une proteine anti-apoptotique incriminee dans le cancer. Des echantillons sanguins ont ete preleves chez 28 patients presentant une LMA, soit de novo soit a la suite d’un syndrome myelodysplasique, et chez 25 controles sains non relies. Dans quelques echantillons, la proteine p53 proapoptotique et les oligonucleosomes ont aussi ete mesures. Chez les controles, bcl-2 etait de 90,6 ± 27,8 U/ml, alors que p53 n’a ete detectee que dans 72 % des echantillons (0,15 ± 0,17 ng/ml); bcl-2 et p53 etaient inversement correlees. Les oligonucleosomes ont ete detectes dans tous les echantillons controles mais a un niveau faible et sans correlation a bcl-2 ni p53. Le niveau de bcl-2 etait plus eleve chez les patients avec LAM que chez les controles, et meme plus eleve chez les patients avec une LAM de novo que chez ceux avec une LMA secondaire. Chez l’ensemble des patients, bcl-2 etait correlee a la lactate-deshydrogenase et aux leucocytes sanguins, mais plus faiblement aux blastes, et pas du tout au caryotype, a l’antigene cd-40 et au genotype mdr-1. p53 n’a ete detectee que chez un patient avec LAM et les oligonucleosomes etaient plus eleves chez les patients que chez les controles. Etudiee chez 12 patients sans mauvais pronostic cytogenetique, le niveau de bcl-2 etait correle a un mauvais denouement. Ces resultats suggerent que les blastes qui sur-expriment bcl-2 sont devenus resistants a l’apoptose, qualifiant cette proteine de facteur de mauvais pronostic dans la LAM. De plus, la determination des valeurs normales de la proteine bcl-2 pourrait etre utile aux etudes portant sur diverses maladies ou l’apoptose est soit augmentee, soit diminuee ou encore differee. Mots cles: proteine bcl-2; leucemie myeloide aigue; apoptose; syndrome de myelodysplastique;proteine p53.
MoreTranslated text
Key words
apoptosis,bcl 2
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined